Mood Emot.
2018 Nov;16(3):140-151. 10.0000/me.2018.16.3.140.
Comparison of the Bupropion versus Aripiprazole Adjunctive Therapy for the Treatment of Female Depression : Post-Hoc Analyses from a Randomized Prospective Open-Label Multi-Center Study
- Affiliations
-
- 1Department of Psychiatry, Yeungnam University College of Medicine, Yeungnam University Medical Center, Daegu, Korea. annemyanne@hanmail.net
- 2Department of Neuropsychiatry, Dongguk University Kyungju Hospital, Kyungju, Korea.
- 3Department of Neuropsychiatry, Daegu Fatima Hospital, Daegu, Korea.
- 4Department of Psychiatry, Catholic University of Daegu School of Medicine, Daegu, Korea.
- 5Department of Psychiatry, Kyungpook National University School of Medicine, Daegu, Korea.
- 6Department of Neuropsychiatry, College of Medicine, Pochon Cha University, Cha Hospital, Gumi, Korea.
- KMID: 2434871
- DOI: http://doi.org/10.0000/me.2018.16.3.140
Abstract
OBJECTIVES
The purpose of this study was to examine effects of adjunctive aripiprazole versus bupropion, on depressive symptoms of female depression.
METHODS
Sixty six female patients with major depressive disorders were enrolled from a six-week, randomized prospective open-label multi-center study. Participants were randomized to receive aripiprazole (2.5-10 mg/day) or bupropion (150-300 mg/day). Montgomery Asberg Depression Rating Scale, 17-item Hamilton Depression Rating scale (HAM-D17), Iowa Fatigue Scale, Drug-Induced Extrapyramidal Symptoms Scale, Psychotropic-Related Sexual Dysfunction Questionnaire scores, and Clinical Global Impression-Severity (CGI-S) were obtained at baseline and after one, two, four, and six weeks. Changes on individual items of HAM-D17 were assessed as well as on composite scales (anxiety, insomnia and drive), and on four core subscales that capture core depression symptoms.
RESULTS
Overall, both treatments improved depressive symptoms, without causing serious adverse events. There were significant differences in the HAM-D17 total score (p=0.046) and CGI-S (p=0.004), between aripiprazole and bupropion augmentation, favoring aripiprazole over bupropion. Aripiprazole revealed significantly greater effect size in depressed mood (p=0.006), retardation (p=0.005), anxiety psychic (p=0.032), and general somatic symptom (p=0.01).
CONCLUSION
While both treatments were effective, results of this study suggested that aripiprazole may be preferable, in treating general and core symptoms of female depression.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Augmentation of Aripiprazole versus Bupropion on Specific Symptoms of Depression in Older Adult Patients : A Post-Hoc, Multi-Center, Open-Label, Randomized Study
- A Meta-Analysis Comparing Open-Label versus Placebo- Controlled Clinical Trials for Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: Lessons and Promises
- Eight-Week Prospective Open-Label Trial of the Treatment Efficacy of Aripiprazole in Children with Tourette Syndrome
- Bupropion for Interferon-Alpha-Induced Depression in Patients with Hepatitis C Viral Infection: An Open-Label Study
- Adjunctive Treatment with Aripiprazole for Risperidone-Induced Amenrrhea
